NGM Bio to Present at Three Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NGM Biopharmaceuticals (NGM) announced that CEO David J. Woodhouse, Ph.D., will present at three investor conferences. The presentations are scheduled for:
- November 18, 2020: Jefferies Virtual London Healthcare Conference at 12:00 PM ET
- November 18, 2020: Stifel Virtual Healthcare Conference at 2:40 PM ET
- November 23, 2020: 32nd Annual Piper Sandler Virtual Healthcare Conference at 12:00 PM ET
A live webcast will be available on the NGM website, and a replay of the presentation will be archived for 90 days.
Details
News Market Reaction – NGM
The recorded move for NGM in the trading session of this news was -2.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at three upcoming investor conferences.
Wednesday, November 18, 2020
Event: Jefferies Virtual London Healthcare Conference
Time: 12:00 pm ET
Wednesday, November 18, 2020
Event: Stifel 2020 Virtual Healthcare Conference
Time: 2:40 pm ET
Monday, November 23, 2020
Event: 32nd Annual Piper Sandler Virtual Healthcare Conference
Time: 12:00 pm ET
A live webcast of these presentations will be available under the Investors and Media section of NGM’s website at https://ir.ngmbio.com/events-presentations. A replay of the presentation will be archived on NGM’s site for 90 days following the event.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit us at www.ngmbio.com for more information.
| Investor Contact: Alex Schwartz ir@ngmbio.com | Media Contact: Liz Melone media@ngmbio.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.